The Waldenstrom macroglobulinemia market is witnessing steady growth driven by advances in targeted therapies, particularly BTK inhibitors like IMBRUVICA and BRUKINSA. Rising awareness, improved ...

Collection of ethnicity data in clinical research has been poor historically, but is essential to ensure that interventions are effective and safe across diverse populations. These data are needed to ...

Global markets have been seesawing this week, as traders digest the latest trade tariff news. Overnight, Asia-Pacific markets ...

Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its Hold rating and $100 price target on Merck & Co., Inc. (NYSE:MRK) after a vote ...

DelveInsight's, “Melanoma Pipeline Insight” report provides comprehensive insights about 150+ companies and 170+ pipeline ...

StudyFormycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206 10.07.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

Italy’s Robin Foà, MD, an iconic European clinician-researcher, has been at forefront of hematology’s transformation for half ...

HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

A new study led by Johns Hopkins researchers has identified a significant gap between the number of U.S. patients for whom cholesterol-lowering drugs ...

Researchers examine survival and cancer recurrence in patients with glottic carcinomas receiving one of two treatments.

KW-3902IV: Merck Sharp & Dohme LLC Relaxin: Corthera, Inc. Dapagliflozin: AstraZeneca GSK716155: GlaxoSmithKline tolvaptan: Otsuka Pharma nesiritide: Scios, Inc. Nesiritide: Janssen Pharma ...